$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx

$cnbx Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000168316822004948 Filed on July 14, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$314.8K	$386.0K	$399.7K
YoY Change	151.16%	207.75%	13.58%
% of Gross Profit
Research & Development	$163.6K	$249.1K	$330.6K
YoY Change	-65.27%	-54.79%
% of Gross Profit
Depreciation & Amortization	$47.29K	$48.83K	$50.59K
YoY Change	-7.24%	-12.71%	-10.46%
% of Gross Profit
Operating Expenses	$478.4K	$635.0K	$730.3K
YoY Change	-19.78%	-6.1%	9.34%
Operating Profit		-$635.0K	-$730.3K
YoY Change		-6.1%
Interest Expense	-$1.350K	-$46.65K	-$508.6K
YoY Change	-98.41%	-92.8%	-482.1%
% of Operating Profit
Other Income/Expense, Net		-$46.65K	-$508.6K
YoY Change
Pretax Income	-$479.7K	-$681.7K	-$1.239M
YoY Change	-29.57%	-48.51%	131.67%
Income Tax
% Of Pretax Income
Net Earnings	-$479.7K	-$681.7K	-$1.239M
YoY Change	-29.57%	-48.51%	131.67%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.05	-$1.01
Diluted Earnings Per Share	-$391.2K	-$0.05	-$1.011M
COMMON SHARES
Basic Shares Outstanding	1.258M shares	1.239M shares	1.226M shares
Diluted Shares Outstanding		1.239M shares	1.226M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$117.5K	$96.28K	$231.6K
YoY Change	-91.52%	-95.11%	-82.64%
Cash & Equivalents	$117.5K	$96.28K	$231.6K
Short-Term Investments
Other Short-Term Assets	$80.77K	$137.8K	$168.0K
YoY Change	-60.48%	-13.12%	-1.54%
Inventory
Prepaid Expenses	$80.77K	$137.8K
Receivables
Other Receivables
Total Short-Term Assets	$198.3K	$234.1K	$399.6K
YoY Change	-87.54%	-88.99%	-73.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$436.8K	$492.2K	$541.0K
YoY Change	-32.06%	-29.07%	-27.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$176.1K	$239.5K	$197.2K
YoY Change	-79.17%	-75.59%	-92.73%
Other Assets
YoY Change
Total Long-Term Assets	$612.9K	$731.6K	$738.2K
YoY Change	-58.82%	-56.32%	-78.67%
TOTAL ASSETS
Total Short-Term Assets	$198.3K	$234.1K	$399.6K
Total Long-Term Assets	$612.9K	$731.6K	$738.2K
Total Assets	$811.2K	$965.7K	$1.138M
YoY Change	-73.65%	-74.6%	-77.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$461.1K	$319.6K	$237.2K
YoY Change	159.78%	65.47%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.759M	$1.605M	$1.325M
YoY Change	101.71%	52.39%	72.66%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.443M	$2.148M	$1.786M
YoY Change	91.94%	46.14%	50.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.443M	$2.148M	$1.786M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.443M	$2.148M	$1.786M
YoY Change	91.94%	46.14%	50.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.55M	-$20.07M
YoY Change	22.13%
Common Stock	$124.00	$124.00
YoY Change	1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.632M	-$1.182M	-$648.0K
YoY Change
Total Liabilities & Shareholders Equity	$811.2K	$965.7K	$1.138M
YoY Change	-73.65%	-74.6%	-77.09%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$479.7K	-$681.7K	-$1.239M
YoY Change	-29.57%	-48.51%	131.67%
Depreciation, Depletion And Amortization	$47.29K	$48.83K	$50.59K
YoY Change	-7.24%	-12.71%	-10.46%
Cash From Operating Activities	-$149.5K	-$375.4K	-$554.8K
YoY Change	-74.3%	-39.08%	-21.01%
INVESTING ACTIVITIES
Capital Expenditures	-$1.150K	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$26.89K	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$25.74K	$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	149.9K	240.0K	0.000
YoY Change		-80.8%	-100.0%
NET CHANGE
Cash From Operating Activities	-149.5K	-375.4K	-554.8K
Cash From Investing Activities	25.74K	0.000	0.000
Cash From Financing Activities	149.9K	240.0K	0.000
Net Change In Cash	26.09K	-135.4K	-554.8K
YoY Change	-104.48%	-121.35%	-148.22%
FREE CASH FLOW
Cash From Operating Activities	-$149.5K	-$375.4K	-$554.8K
Capital Expenditures	-$1.150K	$0.00	$0.00
Free Cash Flow	-$148.4K	-$375.4K	-$554.8K
YoY Change	-74.5%	-39.08%	-21.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001343009
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	CNBX	Held For Trading Investments HeldForTradingInvestments		usd
	CNBX	Held For Trading Investments HeldForTradingInvestments		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-05-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-52403
	dei	Entity Registrant Name EntityRegistrantName	CNBX PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5644005
	dei	Entity Address Address Line1 EntityAddressAddressLine1	#3 Bethesda Metro Center
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1019682	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1300530	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.21
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
	dei	City Area Code CityAreaCode	(877)
	dei	Local Phone Number LocalPhoneNumber	424-2429
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1257927	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	96277	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1386472	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	137815	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	204375	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	234092	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	1590847	usd
CY2022Q2	us-gaap	Investments Investments	239478	usd
CY2021Q3	us-gaap	Investments Investments	845218	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	492170	usd
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	642896	usd
CY2022Q2	us-gaap	Assets Assets	965740	usd
CY2021Q3	us-gaap	Assets Assets	3078961	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	319588	usd
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	177505	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1605000	usd
CY2021Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	871896	usd
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	223645	usd
CY2021Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	223645	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2148233	usd
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1273046	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1238826	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1238826	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1238826	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1238826	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	124	usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	122	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17938589	usd
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	17077715	usd
CY2022Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	3459510	usd
CY2021Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	3459510	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2511455	usd
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1905715	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20069261	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16825718	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1182493	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1805914	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	965740	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3078961	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	249061	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	550842	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1019682	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1300530	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	385945	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	125410	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1455935	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	703323	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	635006	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	676252	usd
	us-gaap	Operating Expenses OperatingExpenses	2475617	usd
	us-gaap	Operating Expenses OperatingExpenses	2003853	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-635006	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-676252	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2475617	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2003853	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2021Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	195968	usd
CY2022Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	46646	usd
CY2021Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	647523	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	767926	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	705412	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-681652	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1323775	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2513297	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	42261	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-603000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-605740	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1004635	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-639392	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1926775	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3849283	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1508662	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.65
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1238826	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1132472	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1221478	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1136642	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1238826	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1132472	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1221478	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1136642	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1805914	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	225289	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	635587	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-605740	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1182493	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-648028	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104926	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	42261	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-681652	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1182493	usd
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	1764524	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1340833	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60125	usd
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	1004635	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	675123	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2513297	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2331943	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3782552	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-1730585	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1340833	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	27125	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	235793	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-1323775	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	2331943	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2513297	usd
	us-gaap	Depreciation Depreciation	151239	usd
	us-gaap	Depreciation Depreciation	169953	usd
	CNBX	Interest On Loans InterestOnLoans	0	usd
	CNBX	Interest On Loans InterestOnLoans	0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	-0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	195968	usd
	CNBX	Due To Related Party Cash Flow DueToRelatedPartyCashFlow	0	usd
	CNBX	Due To Related Party Cash Flow DueToRelatedPartyCashFlow	0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-0	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	60124	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-0	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-0	usd
	CNBX	Convertible Loan Valuation ConvertibleLoanValuation	718392	usd
	CNBX	Convertible Loan Valuation ConvertibleLoanValuation	612420	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	635587	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-66560	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	6326	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142083	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-38001	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1529682	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1911094	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	645968	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	513	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	943	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-513	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	645025	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	240000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2456750	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	CNBX	Costs Of Raising Capital CostsOfRaisingCapital	0	usd
	CNBX	Costs Of Raising Capital CostsOfRaisingCapital	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	240000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2456750	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1290195	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1190680	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1386472	usd
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	777611	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96277	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1986291	usd
	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	225287	usd
	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	1340103	usd
CY2020Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	20-for-1 reverse split
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-one hundred twenty (1:120) reverse split
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20069261	usd
	us-gaap	Salaries And Wages SalariesAndWages	336137	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zK2uWo7P6Bn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Salaries And Wages SalariesAndWages	264061	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	223645	usd
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	223645	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Proceeds From Loans ProceedsFromLoans	240000	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	40000	usd
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	20027	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	225228	usd

Files In Submission

Name	View Source	Status
0001683168-22-004948-index-headers.html	Edgar Link	pending
0001683168-22-004948-index.html	Edgar Link	pending
0001683168-22-004948.txt	Edgar Link	pending
0001683168-22-004948-xbrl.zip	Edgar Link	pending
cnbx-20220531.xsd	Edgar Link	pending
cnbx-20220531_cal.xml	Edgar Link	unprocessable
cnbx-20220531_def.xml	Edgar Link	unprocessable
cnbx-20220531_lab.xml	Edgar Link	unprocessable
cnbx-20220531_pre.xml	Edgar Link	unprocessable
cnbx_ex3101.htm	Edgar Link	pending
cnbx_ex3102.htm	Edgar Link	pending
cnbx_ex3201.htm	Edgar Link	pending
cnbx_ex3202.htm	Edgar Link	pending
cnbx_i10q-5312022.htm	Edgar Link	pending
cnbx_i10q-5312022_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx

2022 Q3 Form 10-Q Financial Statement

#000168316822004948 Filed on July 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX CNBX Pharmaceuticals Inc Stock $cnbx

2022 Q3 Form 10-Q Financial Statement

#000168316822004948 Filed on July 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx